Malignant Head and Neck Neoplasm
Associated Genetic Biomarkers
Malignant head and neck neoplasms most frequently harbor alterations in TP53, CDKN2A, PIK3CA, NOTCH1, and KMT2D .
TP53 Mutation, TP53 Missense, TP53 c.217-c.1178 Missense, PIK3CA Mutation, and NOTCH1 Mutation are the most common alterations in malignant head and neck neoplasm .
There are 5 clinical trials for malignant head and neck neoplasm, of which 5 are open and 0 are completed or closed. Of the trials that contain malignant head and neck neoplasm as an inclusion criterion, 1 is early phase 1 (1 open), 3 are phase 1 (3 open), and 1 is phase 1/phase 2 (1 open).
HLA-A*02, MAGEA4, and TREM1 are the most frequent gene inclusion criteria for malignant head and neck neoplasm clinical trials .
Clr 131, py159, and tak-981 are the most common interventions in malignant head and neck neoplasm clinical trials.
Significant Genes in Malignant Head and Neck Neoplasm
ERBB2 is altered in 4.09% of malignant head and neck neoplasm patients .
ERBB2 is an inclusion eligibility criterion in 1 clinical trial for malignant head and neck neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and malignant head and neck neoplasm as inclusion criteria, 1 is phase 1 (1 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.